Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
2.100
+0.120 (6.06%)
At close: Mar 9, 2026, 4:00 PM EDT
2.010
-0.090 (-4.29%)
After-hours: Mar 9, 2026, 7:54 PM EDT
Alzamend Neuro Employees
As of April 30, 2025, Alzamend Neuro had 7 total employees, including 4 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$924,650
Market Cap
7.99M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 40 |
| KALA BIO | 38 |
| NuCana | 22 |
| Theriva Biologics | 22 |
| Kiora Pharmaceuticals | 12 |
| Immuron | 7 |
| Ernexa Therapeutics | 6 |
| PharmaCyte Biotech | 2 |
ALZN News
- 3 months ago - Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital - PRNewsWire
- 8 months ago - Alzamend Neuro to Present at the 2025 Military Health System Research Symposium - GlobeNewsWire
- 8 months ago - Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - GlobeNewsWire
- 9 months ago - Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule - GlobeNewsWire
- 10 months ago - Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 10 months ago - Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 10 months ago - Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 10 months ago - Alzamend Neuro Announces Reverse Stock Split - GlobeNewsWire